Evidence map›Paper›PMID 38062274›Full record

ArticleBiochemical genetics2024

The Effects of Resveratrol, Gallic Acid, and Piperine on the Expression of miR-17, miR-92b, miR-181a, miR-222, BAX, BCL-2, MCL-1, WT1, c-Kit, and CEBPA in Human Acute Myeloid Leukemia Cells and Their Roles in Apoptosis.

Mahdiyar Iravani Saadi, Javad Moayedi, Fakhroddin Hosseini, Hossain Ali Rostamipour, Zahed Karimi, Zahra Rahimian, Maryam Ahmadyan, Zahra Ghahramani, Mehdi Dehghani, Karim Yousefi and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Biochemical genetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Mahdiyar Iravani SaadiHematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Javad MoayediCenter of Comparative and Experimental Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Fakhroddin HosseiniHematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Hossain Ali RostamipourDepartment of Internal Medicine, Jahrom University of Medical Sciences, Jahrom, Iran.
Zahed KarimiHormozgan University of Medical Sciences, Bandar Abbas, Hormozgan, Iran.
Zahra RahimianHematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Maryam AhmadyanHematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Zahra GhahramaniHematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Mehdi DehghaniHematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Karim YousefiHematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Nadiya KheradmandHematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Mani RamziHematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. ramzim43@yahoo.com.
Nastaran FooladivandaHematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. nastaranfooladi2020@gmail.com.

Funding

Vice-Chancellor of Research, Shiraz University of Medical Sciences, Shiraz, Iran grant No. 94-01-104-11279
6 · The paper itself

Abstract

MicroRNAs (miRs) play a crucial role in the leukemogenesis and the prognosis of acute myeloid leukemia (AML). This study investigated the therapeutic effects of resveratrol, gallic acid, and piperine as natural anticancer agents on the HL-60 cell line and their roles in apoptosis. In this experimental study, quantitative analysis of miRs, including miR-17, miR-92b, miR-181a, and miR-222, were performed in 150 newly diagnosed patients with AML by real-time PCR assay. HL-60 cell viability as well as the expression of miRs, BAX, BCL-2, MCL-1, WT1, c-Kit, and CEBPA, were also assessed after transfection with the LNA-miRs and treatment with resveratrol, gallic acid, and piperine. The expression of miR-17 and miR-181a decreased significantly in LNA-anti-miRs. Although HL-60 cell viability decreased in LNA-anti-miR-222, miR-17, and miR-92b, blockade of miR-181a increased the cell viability. Besides, the cell viability increased merely in the piperine-treated group. Compared to untreated cells, miR-17 and miR-92b expression significantly increased in gallic acid- and resveratrol-treated cells. In HL-60 cells treated with resveratrol, gallic acid, and piperine, the expression of miR-181a was also increased significantly. The expression of BAX was also increased in resveratrol and piperine-treated groups. Compared to untreated cells, the expression of c-Kit increased significantly in the piperine-treated group; however, it decreased in the resveratrol-treated group. LNA-anti-miRs may be a promising agent for the treatment of AML. All three compounds used in this study showed anticancer effects, which can exert the desired outcome in patients with AML.

Indexed as

AlkaloidsApoptosisbcl-2-Associated X ProteinBenzodioxolesGallic AcidLeukemia, Myeloid, AcuteMicroRNAsMyeloid Cell Leukemia Sequence 1 ProteinPiperidinesPolyunsaturated AlkamidesProto-Oncogene Proteins c-bcl-2ResveratrolAdultCCAAT-Enhancer-Binding ProteinsFemaleHL-60 CellsAlkaloidsBAX protein, humanbcl-2-Associated X ProteinBCL2 protein, humanBenzodioxolesCCAAT-Enhancer-Binding ProteinsCEBPA protein, humanGallic AcidKIT protein, humanMCL1 protein, humanMicroRNAsMIR222, humanMIRN17 microRNA, humanMIrn181 microRNA, humanMIRN92 microRNA, humanMyeloid Cell Leukemia Sequence 1 ProteinPiperidinespiperinePolyunsaturated AlkamidesProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-kitResveratrolAcute myeloid leukemiaApoptosisCytogeneticsGallic acidMicroRNAPiperineResveratrol

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.